Vaxxinity Inc. Class A (VAXX)
$0.00
$-0.09
(-99.89%)
As on 26-Aug-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-14 Mln
-
ROE
-1.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
112,910,552
5 Years Aggregate
CFO
$-240.33 Mln
EBITDA
$-303.96 Mln
Net Profit
$-319.76 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vaxxinity Inc. Class A (VAXX)
| -- | -- | -- | -- | -96.4 | -- | -- |
|
BSE Sensex*
| -8.8 | 0.5 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Vaxxinity Inc. Class A (VAXX)
| -39.3 | -75.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vaxxinity Inc. Class A (VAXX)
|
0.0 | 0.0 | 0.0 | -49.9 | -- | -268.9 | -- | 0.0 |
| 88.6 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 77.9 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.3 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 106.9 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 357.5 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 543.7 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 611.6 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 367.9 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 149.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Vaxxinity Inc. Class A (VAXX)
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2... clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. Read more
-
Co-Founder & Executive Chairman of the Board
Mr. Louis Garfield Reese IV
-
Co-Founder & Executive Chairman of the Board
Mr. Louis Garfield Reese IV
-
Headquarters
Merritt Island, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vaxxinity Inc. Class A (VAXX)
What is the current share price of Vaxxinity Inc Class A (VAXX) Today?
The share price of Vaxxinity Inc Class A (VAXX) is $0.00 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Vaxxinity Inc Class A (VAXX) has given a return of -96.44% in the last 3 years.
What is the current PB & PE ratio of Vaxxinity Inc Class A (VAXX)?
Since, TTM earnings of Vaxxinity Inc Class A (VAXX) is negative, P/E ratio is not available.
The P/B ratio of Vaxxinity Inc Class A (VAXX) is 0.01 times as on 21-Aug-2026, a 100 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-1,899.31 |
8.06 |
2022 |
-2.35 |
2.84 |
2021 |
-5.13 |
5.47 |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Vaxxinity Inc Class A (VAXX)?
The 52-week high and low of Vaxxinity Inc Class A (VAXX) are Rs 0.02 and Rs 0.00 as of 28-Aug-2026.
What is the market cap of Vaxxinity Inc Class A (VAXX)?
Vaxxinity Inc Class A (VAXX) has a market capitalisation of $ 0 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Vaxxinity Inc Class A (VAXX)?
Before investing in Vaxxinity Inc Class A (VAXX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.